TITLE

When Averages Hide Individual Differences in Clinical Trials

AUTHOR(S)
Kent, David; Hayward, Rodney
PUB. DATE
January 2007
SOURCE
American Scientist;Jan/Feb2007, Vol. 95 Issue 1, p60
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The authors argue that analyzing the results of clinical trials to expose individual patients' could yield more detailed information doctors need to make better treatment decisions. They believe that to be truly useful, clinical trials must routinely include analyses that combine risk factors into risk scores or indices.
ACCESSION #
23498752

 

Related Articles

  • Involving consumers in designing, conducting, and interpreting randomised controlled trials: questionnaire survey. Hanley, Bec; Truesdale, Ann; King, Andy; Elbourne, Diana; Chalmers, Iain // BMJ: British Medical Journal (International Edition);03/03/2001, Vol. 322 Issue 7285, p519 

    Conclusions: Consumer involvement in the design and conduct of controlled trials seems to be growing and seems to be welcomed by most researchers. Such involvement seems likely to improve the relevance to consumers of the questions addressed and the results obtained in controlled trials.

  • Statistics Notes: Concealing treatment allocation in randomised trials. Altman, Douglas G; Schulz, Kenneth F // BMJ: British Medical Journal (International Edition);8/25/2001, Vol. 323 Issue 7310, p446 

    Discusses the importance of concealing treatment allocation until a patient has entered a randomised clinical trial. Attempts to eliminate bias; How to ensure that allocation sequence will be concealed, including using external help; Difference between randomised and double blind trials.

  • Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. Evans; Pocock; Lievre, Michel; Menard, Joel; Bruckert, Eric; Cogneau, Joel; Delahaye, Francois; Giral, Philippe; Leitersdorf, Eran; Luc, Gerald; Masana, Luis; Moulin, Philippe; Passa, Philippe; Pouchain, Denis; Siest, Gerard // BMJ: British Medical Journal (International Edition);03/10/2001, Vol. 322 Issue 7286, p603 

    Discusses premature discontinuation of clinical trial for reasons not related to efficacy, safety or feasibility. Reasons why some trials are discontinued prematurely by their sponsor for strategic reasons; How public financial and scientific participation in some trials and increasing the...

  • Monitoring and Ensuring Safety During Clinical Research. Morse, Michael A.; Califf, Robert M.; Sugarman, Jeremy // JAMA: Journal of the American Medical Association;3/7/2001, Vol. 285 Issue 9, p1201 

    Addresses concerns regarding the protection of human subjects in clinical trials. Description of the manner in which adverse event reporting might function to enhance safety; Role of data monitoring committees in using aggregate data from these reports; Problems that exist for institutional...

  • Intention-to-treat analysis: Protecting the integrity of randomization. Mahaniah, Kiame J.; Rao, Goutham // Journal of Family Practice;Aug2004, Vol. 53 Issue 8, p644 

    Randomization is a crucial part of most clinical trials. The purpose of randomization in a trial comparing 2 groups is to ensure that the groups differ only with respect to the interventions being compared. Randomization determines not only which treatment subjects receive, but also how the...

  • CONSORT statement: extension to cluster randomised trials. Campbell, Marion K.; Elbourne, Diana R.; Altman, Douglas G. // BMJ: British Medical Journal (International Edition);3/20/2004, Vol. 328 Issue 7441, p702 

    Offers a look at the effective reporting of randomized controlled trials. Guidelines in the Consolidated Standards of Reporting Trials (CONSORT) statement; Discussion of methodological issues in cluster randomized trials; Quality of reporting of cluster trials; Extension of CONSORT statement to...

  • A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants. Lene Thorsen; Kerry Courneya; Clare Stevinson; Sophie Fosså // Supportive Care in Cancer;Sep2008, Vol. 16 Issue 9, p987 

    Abstract Introduction  We reviewed physical activity (PA) studies in prostate cancer (PC) survivors investigating (a) the effects of PA on health outcomes, (b) the prevalence of PA, and (c) the determinants of PA. Materials and methods  A systematic search of the literature...

  • Communicating the Results of Clinical Research to Participants: Attitudes, Practices, and Future Directions. Shalowitz, David I.; Miller, Franklin G. // PLoS Medicine;May2008, Vol. 5 Issue 5, pe91 

    The authors discuss the available data on the effects of communicating aggregate and individual research results on participants, investigators, and the research enterprise.

  • Predictors of New-Onset Kidney Disease in a Community-Based Population. Fox, Caroline S.; Larson, Martin G.; Leip, Eric P.; Culleton, Bruce; Wilson, Peter W. F.; Levy, Daniel // JAMA: Journal of the American Medical Association;2/18/2004, Vol. 291 Issue 7, p844 

    Context: Kidney disease is associated with an increased risk for the development of cardiovascular disease and end-stage renal disease; however, risk factors for kidney disease have not been well studied. Objective: To identify predictors of the development of new-onset kidney disease. Design,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics